Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Mutational change of CTX-M-15 to CTX-M-127 resulting in mecillinam resistant Escherichia coli during pivmecillinam treatment of a patient

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. ESBL-production in Escherichia coli and Klebsiella pneumoniae isolates from Nigeria

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. A mariner transposon vector adapted for mutagenesis in oral streptococci

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Exposure of consumers to substandard antibiotics from selected authorised and unauthorised medicine sales outlets in Ghana

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Oral amoxicillin and amoxicillin–clavulanic acid: properties, indications, and usage

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. A clear conscience is the sure sign of a bad memory: Vancomycin-resistant enterococci and rectal thermometers

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

  4. Clinical experiences with a new system for automated hand hygiene monitoring: A prospective observational study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Pivmecillinam (amdinocillin pivoxil) is the recommended first-choice antibiotic used to treat urinary tract infections (UTIs) in Denmark. The frequency of mutation to mecillinam (MEC) resistance is described as high in vitro; however, treatment of UTI has a good clinical response and prevalence of mecillinam resistance in Escherichia coli remains low despite many years of use. We describe occurrence of in vivo mecillinam resistance in a clinical isolate of ESBL-producing E. coli following pivmecillinam treatment. The identified phenotypic differences in the mecillinam resistant isolate compared with the original mecillinam susceptible isolate were a full-length LPS with O-antigen (O25), mecillinam resistance and a lower MIC for ceftazidime. Regarding genotype, the resistant isolate differed with a mutation in blaCTX-M-15 to blaCTX-M-127 , loss of a part of a plasmid and a genomic island, respectively, and insertion of a transposase in wbbL, causing the rough phenotype. The observed mecillinam resistance is expected to be caused by the mutation in blaCTX-M-15 with additional contribute from the serotype shift. We continue to recommend the use of pivmecillinam as first-line treatment for UTI.

OriginalsprogEngelsk
Artikelnummere941
TidsskriftMicrobiologyOpen
Vol/bind8
Udgave nummer12
Sider (fra-til)1-4
Antal sider4
ISSN2045-8827
DOI
StatusUdgivet - dec. 2019

Bibliografisk note

© 2019 The Authors. MicrobiologyOpen published by John Wiley & Sons Ltd.

ID: 58060601